Investors

Copyright Nasdaq. Minimum 15 minutes delayed.

Investor Overview

We are a company focused on the development of new treatment options for women and couples struggling with infertility. Each OvaScience treatment is based on the Company’s proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPC℠) cells – immature egg cells found within the outer ovarian cortex. 

OvaPrime is a potential fertility treatment that could help restore a woman’s egg production and OvaTure is a potential fertility treatment that eliminates the need for ovarian hormone stimulation. OvaScience’s AUGMENT treatment, designed to improve embryo development and pregnancy rates, is available in Japan under an exclusive license to IVF Japan. OvaScience’s treatments are not available in the United States.

More »

Recent News

Date Title and Summary  
Toggle Summary OvaScience Reports First Quarter 2018 Financial Results and Provides Business Update
WALTHAM, Mass. --(BUSINESS WIRE)--May 3, 2018-- OvaScience SM (Nasdaq:OVAS), a company focused on the development of new treatment options for women and couples struggling with infertility, today reported financial results for the first quarter ended March 31, 2018 and provided a business update.
View HTML
Toggle Summary OvaScience Reports Fourth Quarter and Year-End 2017 Financial Results
– Initial Data from First 20 Patients in Phase 1 Clinical Trial of OvaPrime Indicates Safety and Tolerability; Conducting Additional Preclinical Studies to Optimize Proposed Phase 1b/2a Clinical Trial – – Appointed James Lillie, Ph.D. as Chief Scientific Officer to Lead Advancement of OvaTure
View HTML
Toggle Summary OvaScience Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--Mar. 12, 2018-- OvaScience SM , Inc. (NASDAQ: OVAS), a company focused on the discovery, development and commercialization of new treatment options for women and families struggling with infertility, today announced the grant of an inducement award to its newly
View HTML
Toggle Summary OvaScience to Host Fourth Quarter and Fiscal Year 2017 Financial Results Conference Call
WALTHAM, Mass. --(BUSINESS WIRE)--Mar. 8, 2018-- OvaScience℠ (NASDAQ: OVAS), a company focused on the discovery, development and commercialization of new treatment options for women and families struggling with infertility, today announced that it will host a conference call at 4:30 p.m.
View HTML

More »

Upcoming Events

There are currently no events to display.
Analyst Coverage
Firm Analyst
H.C. Wainwright & Co., LLC

OvaScience, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding OvaScience, Inc.’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of OvaScience, Inc. or its management. OvaScience, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.